Larvol Delta - Avadel-Pharmaceuticals-Achieves-Enrollment-Target-in-RESTON-Phase-3-Pivotal-Trial-of-FT218-for-Excessive-Daytime-Sleepiness-and-Cataplexy-in-Patients-with-Narcolepsy

once nightly oxybate formulation - Jazz

sodium oxybate ER (FT218) - Avadel

Xyrem (sodium oxybate) - Jazz, UCB, Bausch Health

http://www.globenewswire.com/news-release/2019/11/25/1951917/0/en/Avadel-Pharmaceuticals-Achieves-Enrollment-Target-in-REST-ON-Phase-3-Pivotal-Trial-of-FT218-for-Excessive-Daytime-Sleepiness-and-Cataplexy-in-Patients-with-Narcolepsy.html

Nov 25, 2019

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next